Hemophilia gene therapy represents a groundbreaking advancement in the management of hemophilia B, offering hope for patients who have long battled with this bleeding disorder.This innovative treatment, exemplified by the recently FDA-approved Hemgenix, aims to address the underlying genetic causes of hemophilia by correcting the defect in the clotting factor IX gene.